Saturday, December 06, 2014

Clinical trial design for treatment of Ebola virus disease versus Ebola vaccine

›
Ebola outbreak in West Africa has brought a lot of attentions to this deadly virus. The world is so unprepared for the Ebola treatment and...
1 comment:
Monday, December 01, 2014

FDA's Priority Review Voucher Programs

›
A voucher is a bond of the redeemable transaction type which is worth a certain monetary value and which may be spent only for specific reas...
Monday, November 24, 2014

FDA's Position on Use of SI Units for Lab Tests

›
Previously, I wrote an article to discuss the SI unit versus US conventional unit . FDA actually issued its position statement about these t...
2 comments:
Sunday, November 16, 2014

VALOR Trial - A Successful and Failed Phase III Study with Adaptive Sample Size Re-stimation for Promising Zone

›
Motivated by searching for the innovative clinical trial methodologies to increase the clinical trial success and minimize the clinical tri...
2 comments:
Saturday, November 01, 2014

Standard of Care (SOC) as Control Group in Clinical Trials

›
For randomized, controlled clinical trials, the selection of the control group is one of the key issues in the study design. This is why IC...
1 comment:
Saturday, October 18, 2014

The fixed margin method or the two confidence interval method for obtaining the non-inferiority margin

›
For non-inferiority clinical trials, the key issue is to pre-specify the non-inferiority margin and the non-inferiority margin has to be ba...
1 comment:
Saturday, September 13, 2014

N of 1 Clinical Trial Design and its Use in Rare Disease Studies

›
In the beginning (February) of this year, I attended a workshop titled “Clinical Trial Design for Alpha-1 Deficiency: A Model for Rare Dise...
Saturday, September 06, 2014

Full Analysis Set and Intention-to-Treat Population in Non-randomized Clinical Trials?

›
Intention to treatment principle has now been an routine term in the statistical analysis for randomized, controled clinical trials. If a p...
3 comments: